<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114386</url>
  </required_header>
  <id_info>
    <org_study_id>RFPS-2006-8-334056</org_study_id>
    <nct_id>NCT01114386</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)</brief_title>
  <official_title>Clinical, Functional and Biological Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure(CHF) in Stable Conditions and During Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agenzia Italiana del Farmaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Modena and Reggio Emilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cigarette smoking, the major risk factor for COPD, causes not only airway and lung&#xD;
      inflammation, but also systemic effects. These systemic effects of smoking could&#xD;
      substantially contribute to the development of chronic diseases, other than COPD,&#xD;
      particularly chronic heart failure (CHF). The aim of this project is to assess the frequency&#xD;
      and severity of CHF and COPD in outpatients with history of smoking referred to Hospital&#xD;
      because of dyspnea and/or chronic cough.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit 100 patients older than 50 years with diagnosis of COPD and/or CHF. COPD is&#xD;
      defined by presence of fixed airflow obstruction (post-bronchodilator FEV1/FVC less than 70%)&#xD;
      according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines. Each patient&#xD;
      will be characterized by medical history and physical examination. Patients with a diagnosis&#xD;
      of COPD must have: 1) had a history of chronic respiratory symptoms, i.e., cough and sputum&#xD;
      and/or breathlessness and only occasional wheezing (SGRQ and MMRC Questionnaire); 2) they had&#xD;
      to be smokers or ex-smokers with more than 10 pack-years, and 3) a documented absence of a&#xD;
      history of variable airflow obstruction and/or diagnosis of asthma. Each patient will perform&#xD;
      pulmonary function tests, including reversibility to inhaled bronchodilator (400 µg&#xD;
      albuterol); arterial blood gases, and routine blood tests. In addition, each patient will&#xD;
      undergo regular PA/LL chest x-ray. The diagnosis of CHF is established according to the&#xD;
      criteria of European Society of Cardiology. At time of entry in the study, all patients will&#xD;
      be in clinically stable condition (ie, no changes in medication dosage or frequency, and no&#xD;
      exacerbations of disease or hospital admissions in the preceding 6 weeks). Clinical and&#xD;
      biological follow-up of these patients will be prospectively followed for 2 years, from 2009&#xD;
      to 2011.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>COPD</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>COPD patients, CHF patients</arm_group_label>
    <description>COPD and CHF patients with smoking history (&gt; 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung function testing, echocardiography, blood sampling</intervention_name>
    <description>All patients will undergo to:&#xD;
physical examination&#xD;
6' Minute Walk test&#xD;
pulmonary function testing (spirometry + volumes and reversibility testing)&#xD;
carbon monoxide diffusing capacity (DLCO) with single-breathe technique&#xD;
ECG&#xD;
echocardiography</description>
    <arm_group_label>COPD patients, CHF patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling for routine (haemachrome and differential cells blood count, bilirubin,&#xD;
      cholesterol, high density lipoprotein, low density lipoprotein, glycemia, blood urea, blood&#xD;
      electrolytes (sodium, potassium, chloride), glutamic-oxaloacetic transaminase,&#xD;
      glutamic-pyruvic transaminase, γGT, triglycerides, creatinine, uric acid, creatine&#xD;
      phosphokinase, glycosylated haemoglobin).&#xD;
&#xD;
      Blood sampling for selected biomarkers: NTBNP, HS-PCR and IL-6, IL1-β, cellular receptor D6&#xD;
      and TIR8, IL-1 decoy receptor PTX3.&#xD;
&#xD;
      Measurement of arterial blood gases.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients older than 50 years with diagnosis of COPD and/or CHF, male or female, smokers&#xD;
        or ex-smokers with more than 10 pack-years, in stable conditions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasians&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Smoking history &gt; 10 pack years&#xD;
&#xD;
          -  Diagnosis of COPD according to GOLD 2008 and/or diagnosis of CHF according to ESC 2008&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bronchial asthma&#xD;
&#xD;
          -  Fixed airflow limitation due to other chronic diseases such as cystic fibrosis,&#xD;
             bronchiolitis obliterans organizing pneumonia (BOOP), bronchiectasis, TBC etc.&#xD;
&#xD;
          -  Combined restrictive-obstructive functional impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo M Fabbri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Modena and Reggio Emilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Modena and Reggio Emilia</investigator_affiliation>
    <investigator_full_name>Leonardo M. Fabbri</investigator_full_name>
    <investigator_title>Professor Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Cough</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

